Overview

Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses

Status:
Completed

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

We want to see if Zavesca (or miglustat) is safe and can be tolerated by patients with acute infantile onset GM2 gangliosidosis - classical Tay-Sachs and infantile onset Sandhoff disease. We know that miglustat inhibits the formation of GM2 ganglioside, the compound that is stored in the brains of children with Tay-Sachs and Sandhoff disease. Since it inhibits the synthesis of ganglioside, miglustat may be able to reduce or delay the onset of clinical symptoms.

Phase:

Phase 3

Details

Lead Sponsor:

Children's National Research Institute
Children's Research Institute

Collaborator:

Actelion

Treatments:

1-Deoxynojirimycin
Miglustat